ETX-19477

· 858 Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ETX-19477, covering 2026-03-27 to 2026-03-27. Get the full timeline:

Most recent: Clinical Trial Update: A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies [Phase 1, Phase 2]